REG - AstraZeneca PLC - AZN new Head of Investor Relations Joris Silon

AstraZenecaAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260108:nRSH0610Oa&default-theme=true

RNS Number : 0610O  AstraZeneca PLC  08 January 2026

 

8 January 2026

AstraZeneca appoints Joris Silon as Head of Investor Relations

AstraZeneca's new head of Investor Relations, Joris Silon, succeeds Andy
Barnett on 1 March 2026, and will be based in Cambridge, UK.

 

Joris is moving from his role as the country president of AstraZeneca US where
he led and delivered significant growth for the Company in its largest market.
Joris brings extensive pharmaceutical experience, having joined the Company in
2000 and has held leadership positions in Asia, Europe and the US.

 

Aradhana Sarin, Chief Financial Officer, said "I am delighted that such a
highly experienced and talented leader as Joris will lead our Investor
Relations team through our next wave of growth. I would also like to thank
Andy Barnett for his remarkable leadership of our Investor Relations team over
the past 4 years and wish him the best of luck as he transitions to an
important new role within the Company."

 

Notes

 

AstraZeneca (https://www.astrazeneca.com/)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are
sold in more than 125 countries and used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the
Company on Social Media @AstraZeneca
(https://www.linkedin.com/company/astrazeneca) .

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUBRBRNSUARAR



            Copyright 2019 Regulatory News Service, all rights reserved